Rehovot, Israel — August 11, 2025 — Leads & Copy — BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) reported its financial and operational results for the second quarter ended June 30, 2025, highlighting a 41% year-over-year revenue increase to $8.5 million, with gross margins expanding to 60%. The company’s U.S. active VINIA® users reached 65,000, generating over $60 million in cumulative revenue since the USA launch in May 2021. Business growth was balanced, with new products representing approximately 20% and the core VINIA capsule business driving around 80% of growth. BioHarvest also secured a new Stage 1 CDMO contract for a plant-based fragrance compound and launched VINIA® Daily Chews 2X Formula.
Management expects third-quarter revenues of at least $9.1 million and anticipates reaching adjusted EBITDA breakeven in the fourth quarter of 2025. The company will launch three growth initiatives in the second half of 2025: a ‘Health Pros’ Professional Affiliate Program, VINIA® BloodFlow Hydration Solution, and an AI-Enabled CDMO Discovery Phase.
Ilan Sobel, CEO of BioHarvest Sciences, noted the strong operational execution and progress toward adjusted EBITDA breakeven, driven by growth in the core VINIA® capsule business and CDMO contributions.
Dave Ryan, VP Investor Relations, +1 (604) 622-1186, info@bioharvest.com
Lucas A. Zimmerman, Managing Director, MZ Group – MZ North America, +1 (949) 259-4987, BHST@mzgroup.us
Source: BioHarvest Sciences Inc.
Source: BioHarvest Sciences Inc.
